Microarray Technology vs Next Generation Sequencing

Hybridization-based microarrays read a fixed, pre-known panel of probes cheaply; NGS reads the actual sequence and finds what you didn't design for. One is a price-list lookup, the other is discovery.

The core difference nobody states plainly

A microarray is a hybridization lookup table. You print probes for sequences you already know about, wash labeled sample over them, and measure which spots glow. It can only ever answer questions you designed into the chip. NGS, by contrast, physically reads the bases — millions of short reads aligned or assembled — so it returns the sequence as it actually is, including the parts you never anticipated. That is the whole game. Arrays measure presence/intensity at known coordinates; NGS measures sequence and depth at every coordinate it covers. Everything else — cost, throughput, error profile — is downstream of this. If your question is 'how much of X is here' and X is fully known, an array is a fine, fast instrument. If your question is 'what is actually in this sample,' the array cannot answer it and no amount of cleverness changes that.

Where microarrays still win

Don't let the NGS hype tell you arrays are dead — they aren't, and pretending otherwise is sloppy. For genotyping a fixed panel of validated SNPs at massive scale, arrays remain cheaper per sample, faster end-to-end, and dramatically lighter on compute and storage. A SNP chip gives you a clean genotype table in hours with a mature, boringly reliable pipeline; no alignment, no variant-calling tuning, no terabytes of FASTQ to babysit. Agricultural breeding programs, large population cohorts, and pharmacogenomic panels run array genotyping precisely because the targets never change and the economics at 50,000 samples are brutal. Expression arrays linger for the same reason in cost-sensitive, well-characterized assays. The array's weakness — it only sees what you designed — becomes a feature when the design is the entire, stable question. Use the cheap tool for the solved problem.

Where NGS pulls decisively ahead

The moment your question contains the word 'unknown,' arrays are out. NGS detects novel and rare variants, structural rearrangements and gene fusions, copy-number changes, low-frequency somatic mutations in tumors, and full transcriptomes including unannotated isoforms. It does de novo assembly of organisms with no reference. It scales resolution by simply sequencing deeper rather than printing a new chip. Single-cell, metagenomics, liquid biopsy, immune repertoire — none of these are array-shaped problems. Crucially, NGS has a dynamic range arrays can't touch: hybridization intensity saturates and compresses, while read counts are genuinely quantitative across orders of magnitude. Microarrays also suffer cross-hybridization and batch/normalization headaches that NGS largely sidesteps. As per-sample cost fell, the array's one durable advantage — price — eroded toward parity for many designs, leaving NGS ahead on nearly every axis that involves learning something new.

The honest cost and complexity trade

NGS is not free lunch, and anyone selling it that way is lying. You pay in compute, storage, and expertise: raw reads become useful only after alignment, variant calling, and QC that demand real bioinformatics competence and infrastructure. A single deep genome is gigabytes of data and a pipeline you must maintain. Arrays hand you a tidy genotype matrix with a vendor pipeline and a fraction of the storage. Turnaround for a fixed panel can also favor arrays. So the trade is real: NGS buys you discovery and quantitative truth at the price of operational weight; arrays buy you cheap, fast, brittle certainty about a frozen list. My verdict stands because for any forward-looking lab the discovery capability compounds and the chip's design ceiling becomes a wall you hit repeatedly. But if you genuinely have a solved, stable, high-volume genotyping problem, paying the NGS tax is waste, not virtue.

Quick Comparison

Factor	Microarray Technology	Next Generation Sequencing
Discovery of unknown variants	Blind — only detects probes you designed	Reads actual sequence, finds novel/rare/structural variants
Cost per sample (fixed known panel)	Lowest at large scale, mature turnkey pipeline	Higher; cheaper than before but more compute/storage
Quantitative dynamic range	Hybridization intensity saturates and compresses	Read counts quantitative across orders of magnitude
Operational/bioinformatics burden	Light — clean genotype matrix, vendor pipeline	Heavy — alignment, variant calling, TB-scale data
Future-proofing as questions change	Reprint a new chip every time the design changes	Same data answers new questions; scale by sequencing deeper

The Verdict

Use Microarray Technology if: You are genotyping a fixed, validated panel of known SNPs across tens of thousands of samples (GWAS, ag breeding, population screens) and need the lowest cost-per-known-call with a turnkey pipeline.

Use Next Generation Sequencing if: You need to discover anything you didn't pre-specify — novel variants, structural rearrangements, low-frequency somatic mutations, full transcriptomes, or de novo assembly. This is the default for new biology.

Consider: Run a microarray as a cheap first-pass screen, then confirm and characterize the interesting hits with targeted NGS. Many clinical and ag labs already do exactly this rather than picking one religion.

The Bottom Line

Next Generation Sequencing wins

NGS reads the sequence itself instead of asking "is this one probe I already designed lit up?", so it finds novel variants, fusions, and rare alleles a microarray is structurally blind to. Per-sample cost has collapsed to within striking distance of arrays, and you stop re-buying a new chip every time the question changes. Arrays win on price-per-known-target at scale, but a method that can only confirm what you already suspected is a dead end for anything research-grade.